
Immune cell therapy for advanced head and neck cancer helps stabilize disease
A multi-institutional clinical trial conducted at the UNC Lineberger Comprehensive Cancer Center and 21 other U.S. sites found that a single administration of autologous tumor-infiltrating lymphocyte (TIL) cell therapy helped stabilize metastatic head and neck squamous cell carcinoma (HNSCC) in some patients. This finding is significant, as many of these patients had previously undergone multiple treatments without success.